Ke HZ - Search Results

1

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.

Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Ke HZ, et al. Endocrinology. 2004 Apr;145(4):1996-2005. doi: 10.1210/en.2003-1481. Epub 2004 Jan 15. Endocrinology. 2004. PMID: 14726439

2

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Maeda T, Ke HZ, Simmons H, Thompson D. Maeda T, et al. Among authors: ke hz. Clin Calcium. 2004 Oct;14(10):85-93. Clin Calcium. 2004. PMID: 15577137 Review. Japanese.

3

A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia.

Ke HZ, Qi H, Crawford DT, Simmons HA, Xu G, Li M, Plum L, Clagett-Dame M, DeLuca HF, Thompson DD, Brown TA. Ke HZ, et al. J Bone Miner Res. 2005 Oct;20(10):1742-55. doi: 10.1359/JBMR.050605. Epub 2005 Jun 13. J Bone Miner Res. 2005. PMID: 16160732 Free article.

4

A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.

Ke HZ, Crawford DT, Qi H, Simmons HA, Owen TA, Paralkar VM, Li M, Lu B, Grasser WA, Cameron KO, Lefker BA, DaSilva-Jardine P, Scott DO, Zhang Q, Tian XY, Jee WS, Brown TA, Thompson DD. Ke HZ, et al. J Bone Miner Res. 2006 Apr;21(4):565-75. doi: 10.1359/jbmr.051110. Epub 2006 Apr 5. J Bone Miner Res. 2006. PMID: 16598377 Free article.

5

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.

Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WS, Thompson DD. Ke HZ, et al. Bone. 1995 Nov;17(5):491-6. doi: 10.1016/8756-3282(95)00346-2. Bone. 1995. PMID: 8579962

6

Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.

Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD. Ke HZ, et al. Endocrinology. 1998 Apr;139(4):2068-76. doi: 10.1210/endo.139.4.5902. Endocrinology. 1998. PMID: 9528995

7

Parathyroid hormone (1-34) increased total body bone mass in aged female rats.

Simmons HA, Pirie CM, Thompson DD, Ke HZ. Simmons HA, et al. Among authors: ke hz. J Pharmacol Exp Ther. 1998 Jul;286(1):341-4. J Pharmacol Exp Ther. 1998. PMID: 9655878

8

Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia.

Ke HZ, Shen VW, Qi H, Crawford DT, Wu DD, Liang XG, Chidsey-Frink KL, Pirie CM, Simmons HA, Thompson DD. Ke HZ, et al. Bone. 1998 Sep;23(3):249-55. doi: 10.1016/s8756-3282(98)00102-1. Bone. 1998. PMID: 9737347

9

Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.

Ke HZ, Crawford DT, Qi H, Pirie CM, Simmons HA, Chidsey-Frink KL, Chen HK, Jee WS, Thompson DD. Ke HZ, et al. Bone. 1999 Jan;24(1):41-7. doi: 10.1016/s8756-3282(98)00146-x. Bone. 1999. PMID: 9916783

10

Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.

Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD. Ke HZ, et al. Endocrinology. 2000 Apr;141(4):1338-44. doi: 10.1210/endo.141.4.7408. Endocrinology. 2000. PMID: 10746637

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters